Biosketch Uwe Siebert

Uwe Siebert, MD, MPH, MSc, ScD
Professor of Public Health (UMIT)
Adjunct Professor of Health Policy and Management
(Harvard School of Public Health)
Chair, Department of Public Health, Information Systems
and Health Technology Assessment, UMIT
Director, Cardiovascular Research Program, Institute for
Technology Assessment, Dept. of Radiology, MGH,
Harvard Medical School
Biosketch: Uwe Siebert
UMIT - University for Health
Sciences, Medical Informatics
and Technology
Eduard Wallnoefer Center I
A-6060 Hall i.T., Austria
Phone: +43-50-8648-3930
Fax: +43-50-8648-673931
Email direct: uwe.siebert@umit.at
Email PA: public-health@umit.at
Web: www.umit.at
Prof. Uwe Siebert, MD, MPH, MSc, ScD, Professor of Public Health, is the Chair of the Department of
Public Health, Information Systems and Health Technology Assessment at the University for Health
Sciences, Medical Informatics and Technology (UMIT) in Austria and the Director of the Division for Public
Health Decision Modeling, HTA, and Health Economics in the ONCOTYROL – Center for Personalized
Cancer Medicine in Austria. He is also Adjunct Professor of Health Policy and Management at the Harvard
School of Public Health and Associate Professor of Radiology at Harvard Medical School, where he directs
the Program on Cardiovascular Research at the Institute for Technology Assessment, Massachusetts
General Hospital, Boston. He has an adjunct teaching appointment at the School of Public Health and
Epidemiology at the University of Munich.
After medical school, Prof. Siebert worked for several years as a physician in international public health
projects. He then earned an MPH at the Munich School of Public Health, and completed an MSc in
Epidemiology and an ScD in Health Policy and Management with a concentration in decision sciences at the
Harvard School of Public Health. Before he started his faculty position at Harvard Medical School, he was
the Director of the Bavarian Public Health Research and Coordinating Center at the University of Munich,
Germany, and completed Visiting Scholarship at the Harvard Center for Risk Analysis.
His research interests include applying evidence-based quantitative methods from public health,
epidemiology, outcomes research, economic evaluation and decision sciences in the framework of health
technology assessments (HTA) as well as in the clinical context of routine health care. His current
substantive research focuses on cancer, cardiovascular disease, diabetes, hepatitis C, HIV, and
neurological disorders. His methodological research is focused on evaluations of public health interventions,
prevention and screening, diagnostic imaging procedures, personalized medicine, information systems as
well as the development of causal decision models.
Prof. Siebert is a member of the Board of Trustees of the Society of Medical Decision Making (SMDM), a
member of the International Expert Committee Advising the Institute for Quality and Efficiency in Health
Care (IQWiG) on the Methods for Economic Evaluations of Health Care Interventions, a member of the Latin
America Consortium Advisory Committee of the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR), a member of the Advisory Board of the Ludwig Boltzmann Institute for Health
Technology Assessment in Austria, a member of the ‘National HTA Strategy’ Expert Group of the Austrian
Ministry of Health, a member of the Working Group "Methods of the Assessment of Cost-Benefit Relations"
of the Scientific Advisory Board of IQWIG, and he has served as a member of the Board of Directors of the
International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He is the Chairman of the
Working Groups "Health Economics" and "Medical Decision Making" of the German Society for Medical
Informatics, Biometry and Epidemiology (GMDS). He is Co-Chair of the "Issues in Methodology Section" of
the SMDM Policy Initiative, Co-Chair of the ISPOR-SMDM Modeling Good Research Practices Task Force,
and a Leadership Member of the ISPOR Personalized Medicine Special Interest Group. He teaches courses
in decision analysis, HTA, economic evaluation, and advanced epidemiologic methods at several
universities and for industry in Europe, USA, and South America. He advises government agencies,
academic institutions and the industry regarding the conduction and impact of health technology
assessments on policy and reimbursement decisions. He has authored more than 200 publications including
HTA reports, textbook chapters, scientific articles, and editorials, and is Associate Editor of the International
Journal of Public Health as well as editorial board member of several other scientific journals.

Selected Publications:
Tonino PAL, De Bruyne B, Pijls NHJ, Siebert U, Ikeno F, van't Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN,
MacCarthy PA, Fearon WF, for the FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous
coronary intervention. New England Journal of Medicine 2009;360(3):213-24.
Siebert U, Bornschein B, Schnell-Inderst P, Rieber J, Pijls N, Wasem J, Klauss V. Measurement of Fractional Flow Reserve to Guide
the Decision on Percutaneous Coronary Interventions. Health Technology Assessment Vol. 15-04. (Series of the German Institute
for Medical Documentation and Information commissioned by the Federal Ministry of Health). Cologne: DIMDI, 2008.
Drummond MF, Schwartz JF, Jönsson BJ, Luce BR, Neumann PJ, Siebert U, Sullivan SD. Key principles for the improved conduct of
health technology assessments for resource allocation decisions. International Journal of Technology Assessment in Health Care
2008;24(3):244–258.
Miksad RA, Zietemann V, Gothe R, Schwarzer R, Conrads-Frank A, Schnell-Inderst P, Stollenwerk B, Siebert U. Progression-free
survival as a surrogate endpoint in advanced breast cancer. International Journal of Technology Assessment in Health Care
2008;24(4):371-83.
Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The Effect of Electronic Prescribing on Medication Errors and Adverse Drug
Events: A Systematic Review. J Am Med Inform Asso 2008;15(5):585-600 [Epub ahead of print]
Lettmeier B; Mühlberger N, Schwarzer E, Sroczynski G, Wright D, Zeuzem S, Siebert U. Market Uptake of New Antiviral Drugs for the
Treatment of Hepatitis C. Journal of Hepatology 2008;49(4):528-36.
Böse-O'Reilly S, Lettmeier B, Gothe RM, Beinhoff C, Siebert U, Drasch G. Mercury as a serious health hazard for children in gold
mining areas. Environmental Research 2008;107(1):89-97.
Mühlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U. Cost-effectiveness of primarily human papillomavirusbased
cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the
German Federal Ministry of Health. International Journal of Technology Assessment in Health Care 2008;24(2):184-92
Institute or Quality and Efficiency in Halth Care (IQWiG). Methods for Assessment of the Relation of Benefits to Costs in the German
Statutory Health Care System. V. 1.0. (Members of the IQWiG International Expert Panel: Attella V, Caro J, Pouvourville G, Henry
D, McGregor M, McGuire A, Nord E, Siebert U) Cologne: IQWiG; January 2008, 69 pages. Internet:
http://www.iqwig.de/download/08-01-24_Methods_of_the_Relation_of_Benefits_to_Costs_Version_1_0.pdf
Siebert U. Cost-Effectiveness. In: King SP III and Yeung AC (eds.). Interventional Cardiology. McGraw-Hill, New York: 2007; 767-82.
Siebert U, Sroczynski G, Hillemanns P, Engel J, Stabenow R, Stegmaier C, Voigt K, Gibis B, Hölzel D, Goldie SJ. The German Cervical
Cancer Screening Model: Development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J
Pub Health 2006;16(2):185-92.
Siebert U. [Decision Analysis]. [German]. In: Schlipköter U, Wildner M (eds.): [Manual of Infectious Diseases Epidemiology]. Hans
Huber, Bern: 2006; 87-95.
Siebert U, Januzzi JL Jr, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to
guide the diagnostic assessment and management of dyspneic patients in the emergency department. American Journal of
Cardiology, 2006;98(6):800-5.
Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K. The cost-effectiveness of testing for hepatitis C in
former injecting drug users. Health Technol Assess 2006;10(32):1-112.
Göhler A, Januzzi JL, Worrell SS, Osterziel KJ, Gazelle GS, Dietz R, Siebert U. A Systematic Meta-Analysis of the Efficacy and
Heterogeneity of Disease Management Programs in Congestive Heart Failure. J Cardiac Failure 2006;12(7):554-67.
Siebert U. Using Decision-Analytic Modeling to Transfer International Evidence from Health Technology Assessment to the Context of
the German Health Care System. A HTA Methods Report. Health Technology Assessment Vol 15. Series of the German Institute
for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security. 90 pages.
Cologne: DIMDI, 2005.
Siebert U, Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in
patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of
Health and Social Security. Int J Technol Assess Health Care 2005;21(1):55-65.
Siebert U, Bornschein B, Walbert T, Dodel R. Systematic assessment of decision models in Parkinson's disease. Value Health
2004;7(5):610-26.
Siebert U, Muth C, Sroczynski G, Velasco-Garrido M, Gerhardus A, Gibis B (eds.). Liquid-Based Preparation and Computer-Assisted
Examination of Cervical Smears in Cervical Cancer Screening. Clinical Effectiveness, Economic Evaluation, and Decision Analysis.
Health Technology Assessment Vol 35. Series of the German Institute for Medical Documentation and Information commissioned
by the Federal Ministry of Health and Social Security. Sankt Augustin: Asgard, 2004;444 pages
Robins JM, Hernán MA, Siebert U. Estimations of the Effects of Multiple Interventions. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL,
eds. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk
Factors. Vol. 1. Geneva: World Health Organization, 2004; 2191-2230.
Wong J, Sylvestre D, Siebert U. Cost-effectiveness of treatment of hepatitis C in injecting drug users. In: Jager J, Limburg W,
Kretzschmar M, Postma M, Wiessing L (eds.). Hepatitis C and Injecting Drug Use: Impact, Costs and Policy Options. EMCDDA
Monographs Vol 7. European Monitoring Center for Drugs and Drug Addiction: Lisbon, 2004;219-241.
Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB. Costeffectiveness
of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut
2003; 52(3): 425-32.
Siebert U. [Transparent Decisions in Public Health Using Systematic Decision Analysis]. [German]. In: Schwartz FW, Badura B, Busse
R, Leidl R, Raspe H, Siegrist J, Walter U (eds.): [The Public Health Book. Health and Health Care]. 2 nd ed. Urban & Fischer:
München, 2003;485-502.
Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? [Editorial]. The European
Journal of Health Economics 2003;4(3):143-50.
For full publication list, see: http://iph.umit.at/ and www.mgh-ita.org